Literature DB >> 1859935

The future of nicotine replacement.

M A Russell1.   

Abstract

Following in the wake of progress forged by nicotine chewing gum, a new generation of nicotine replacement products will soon be available as aids to giving up smoking. These range from nicotine skin patches, which take 6-8 hrs to give very flat steady-state peak blood levels, to nicotine vapour inhalers which mimic the transient high-nicotine boli that follow within a few seconds of each inhaled puff of cigarette smoke. Other products undergoing clinical trials include a nasal nicotine spray and nicotine lozenges. It is argued here that it is not so much the efficacy of new nicotine delivery systems as temporary aids to cessation, but their potential as long-term alternatives to tobacco that makes the virtual elimination of tobacco a realistic future target. Their relative safety compared with tobacco is discussed. A case is advanced for selected nicotine replacement products to be made as palatable and acceptable as possible and actively promoted on the open market to enable them to compete with tobacco products. They will also need health authority endorsement, tax advantages and support from the anti-smoking movement if tobacco use is to be gradually phased out altogether.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859935     DOI: 10.1111/j.1360-0443.1991.tb01825.x

Source DB:  PubMed          Journal:  Br J Addict        ISSN: 0952-0481


  15 in total

1.  Estimating the health consequences of replacing cigarettes with nicotine inhalers.

Authors:  W Sumner
Journal:  Tob Control       Date:  2003-06       Impact factor: 7.552

Review 2.  The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis.

Authors:  J Birtwistle
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 3.  Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review.

Authors:  Konstantinos E Farsalinos; Riccardo Polosa
Journal:  Ther Adv Drug Saf       Date:  2014-04

4.  The smoking population in the USA and EU is softening not hardening.

Authors:  Margarete C Kulik; Stanton A Glantz
Journal:  Tob Control       Date:  2015-06-24       Impact factor: 7.552

Review 5.  Historical and current perspective on tobacco use and nicotine addiction.

Authors:  John A Dani; David J K Balfour
Journal:  Trends Neurosci       Date:  2011-06-21       Impact factor: 13.837

Review 6.  Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy?

Authors:  Tammy Harris Sims; Michael C Fiore
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Nicotine psychopharmacology research contributions to United States and global tobacco regulation: a look back and a look forward.

Authors:  Jack E Henningfield; Mitch Zeller
Journal:  Psychopharmacology (Berl)       Date:  2006-02-04       Impact factor: 4.530

Review 8.  Tobacco harm reduction: Past history, current controversies and a proposed approach for the future.

Authors:  Dorothy K Hatsukami; Dana M Carroll
Journal:  Prev Med       Date:  2020-04-23       Impact factor: 4.018

9.  The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US.

Authors:  Mitchell Zeller; Dorothy Hatsukami
Journal:  Tob Control       Date:  2009-02-24       Impact factor: 7.552

10.  Nicotine addiction: a re-analysis of the arguments.

Authors:  R West
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.